Exelixis (EXEL) shares were down more than 5% in recent Thursday trading after Morgan Stanley downgraded the biotechnology company's stock to equalweight, with a price target of $48.
Trading volume stood at nearly 1.5 million shares, compared with a daily average of 2.8 million.
Price: 43.71, Change: -2.48, Percent Change: -5.37